Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026
Earnings Call Scheduled for 9:30 p.m. ET on June 8, 2026 MILPITAS, Calif., May 26, 2026 /PRNewswire/ — Zepp Health Corporation (“Zepp Health” or... Read more.
Hydreight Technologies Announces Timing of Q1 2026 Financial Results and Investor Webcast
VANCOUVER, BC and LAS VEGAS, May 26, 2026 /PRNewswire/ – Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB:... Read more.
Hydreight Technologies Announces Timing of Q1 2026 Financial Results and Investor Webcast
VANCOUVER, BC and LAS VEGAS, May 26, 2026 /PRNewswire/ – Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB:... Read more.
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/... Read more.
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
Thermostability, immunogenicity and efficacy data against related virusesmay provide rapid starting point for vaccine development PRINCETON, N.J., May 26, 2026 /PRNewswire/... Read more.
ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $10 Million for the First Quarter of 2026
AZOUR, Israel, May 26, 2026 /PRNewswire/ — Ituran Location and Control Ltd. (NASDAQ: ITRN) announced that the Board of Directors approved the distribution... Read more.
ITURAN LOCATION AND CONTROL LTD Announces Dividend Distribution of $10 Million for the First Quarter of 2026
AZOUR, Israel, May 26, 2026 /PRNewswire/ — Ituran Location and Control Ltd. (NASDAQ: ITRN) announced that the Board of Directors approved the distribution... Read more.
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ — Kazia... Read more.
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ — Kazia... Read more.
Tata Elxsi Launches ViTel™, a Material Intelligence Solution for Med-Tech Powered by Viridium AI
ViTel™ helps medical device manufacturers protect margins, accelerate sourcing and engineering decisions, and stay ahead of compliance through AI-powered material... Read more.